107 related articles for article (PubMed ID: 21282425)
1. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.
Cho DY; Ogburn ET; Jones D; Desta Z
Antimicrob Agents Chemother; 2011 Apr; 55(4):1504-9. PubMed ID: 21282425
[TBL] [Abstract][Full Text] [Related]
2. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
Cho DY; Shen JH; Lemler SM; Skaar TC; Li L; Blievernicht J; Zanger UM; Kim KB; Shin JG; Flockhart DA; Desta Z
Drug Metab Pharmacokinet; 2016 Apr; 31(2):107-16. PubMed ID: 27053325
[TBL] [Abstract][Full Text] [Related]
3. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.
Kwara A; Tashima KT; Dumond JB; Poethke P; Kurpewski J; Kashuba AD; Court MH; Greenblatt DJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3527-33. PubMed ID: 21518840
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
Kwara A; Cao L; Yang H; Poethke P; Kurpewski J; Tashima KT; Mahjoub BD; Court MH; Peloquin CA
Pharmacotherapy; 2014 Mar; 34(3):265-71. PubMed ID: 24420746
[TBL] [Abstract][Full Text] [Related]
5. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
[TBL] [Abstract][Full Text] [Related]
6. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
Bélanger AS; Caron P; Harvey M; Zimmerman PA; Mehlotra RK; Guillemette C
Drug Metab Dispos; 2009 Sep; 37(9):1793-6. PubMed ID: 19487252
[TBL] [Abstract][Full Text] [Related]
7. Instability of Efavirenz Metabolites Identified During Method Development and Validation.
Andriguetti NB; Barratt DT; Tucci J; Pumuye P; Somogyi AA
J Pharm Sci; 2021 Oct; 110(10):3362-3366. PubMed ID: 34175301
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study.
Amara AB; Else LJ; Carey D; Khoo S; Back DJ; Amin J; Emery S; Puls RL
Ther Drug Monit; 2017 Dec; 39(6):654-658. PubMed ID: 28953037
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
[TBL] [Abstract][Full Text] [Related]
11. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
[TBL] [Abstract][Full Text] [Related]
13. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
Burhenne J; Matthée AK; Pasáková I; Röder C; Heinrich T; Haefeli WE; Mikus G; Weiss J
Antimicrob Agents Chemother; 2010 Oct; 54(10):4185-91. PubMed ID: 20660679
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers.
Yenny ; Nafrialdi ; Djoerban Z; Setiabudy R
Int J Clin Pharmacol Ther; 2011 Feb; 49(2):162-8. PubMed ID: 21255533
[TBL] [Abstract][Full Text] [Related]
15. In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9.
Iwasaki K; Kitsugi Y; Ikeda K; Yoshikawa T; Hosaka S; Uehara S; Uno Y; Utoh M; Yamazaki H
Biopharm Drug Dispos; 2016 Sep; 37(6):379-83. PubMed ID: 27417918
[TBL] [Abstract][Full Text] [Related]
16. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.
Deng S; Chen XP; Cao D; Yin T; Dai ZY; Luo J; Tang L; Li YJ
Clin Ther; 2009 Jun; 31(6):1256-63. PubMed ID: 19695392
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.
Ma Q; Forrest A; Rosenkranz SL; Para MF; Yarasheski KE; Reichman RC; Morse GD;
Biopharm Drug Dispos; 2008 Mar; 29(2):91-101. PubMed ID: 18041735
[TBL] [Abstract][Full Text] [Related]
18. Ultra high performance liquid chromatography tandem mass spectrometric detection of glucuronides resistant to enzymatic hydrolysis: Implications to doping control analysis.
Kotronoulas A; Marcos J; Segura J; Ventura R; Joglar J; Pozo OJ
Anal Chim Acta; 2015 Oct; 895():35-44. PubMed ID: 26454457
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz.
Mutlib AE; Chen H; Nemeth GA; Markwalder JA; Seitz SP; Gan LS; Christ DD
Drug Metab Dispos; 1999 Nov; 27(11):1319-33. PubMed ID: 10534318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
